TITLE

Sustained-release implants on track for retinal vascular disease treatment

AUTHOR(S)
Boyle, Erin L.; Harcharek, Alexandra; Hasson, Matt; Hsvidas, Cara; Nale, Patricia; Master, Joseph; Pagnani, Michelle; Preston, Courtney
PUB. DATE
February 2011
SOURCE
Ocular Surgery News;2/25/2011, Vol. 29 Issue 4, p23
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article focuses on the discussion given by doctor Elias Reichel concerning the outcomes of the use of Ozurdex and Iluvien implants for the treatment of retinal vascular disease.
ACCESSION #
86439049

 

Related Articles

  • Users of retinal prosthesis system accumulate implant time since FDA approval.  // Ocular Surgery News;2/25/2014, Vol. 32 Issue 4, p32 

    The article reports that 35 subjects have been implanted with the Argus II device, which is also known as the Second Sight, since the U.S. Food and Drug Administration has approved the Argus II retinal prosthesis system according to Dr. Mark S. Humayun, co-inventor of the Argus II device.

  • CenterVue gains FDA 510(k) clearance. Schneider, Rose // Ophthalmology Times;6/15/2014, Vol. 39 Issue 12, p12 

    The article reports that CenterVue's next-generation Macular Integrity Assessment (MAIA) offering advances in scanning laser ophthalmoscopy confocal miicroperimetry has been granted U.S. Food and Drug Administration (FDA) 510(K) clearance.

  • HRS notebook.  // Medical Device Daily;5/13/2013, Vol. 17 Issue 92, p5 

    The article reports that medical device manufacturer nContact received conditional approval for an investigational device exemption from the U.S. Food and Drug Administration (FDA) to begin enrollment in the CONVERGE trial.

  • On-X gets FDA approval for aortic valve anatomic ring. FORD, OMAR // Medical Device Daily;3/ 8/2013, Vol. 17 Issue 46, p1 

    The article offers brief information on the On-X Aortic Prosthetic Valve from On-X Life Technologies.

  • FDA drafts guidance for IDE decisions. McCARTY, MARK // Medical Device Daily;6/20/2013, Vol. 17 Issue 119, p9 

    The article reports on the U.S. Food and Drugs Administration's (FDA) continued guidances for medical devices with a draft that addresses the agency's decisions for investigational device exemptions (DIE). The draft provides a framework for clinical study proposals the agency would have to...

  • Industry Pipeline.  // Ocular Surgery News;2/25/2013, Vol. 31 Issue 4, p44 

    The article reports on various ophthalmic business updates including recent approvals, recent clearances and orphan drug designations. Rescula, a drug released by Sucampo pharmaceuticals Inc. has received approval from U.S. Food and Drug Administration (FDA). U.S. FDA has cleared MultiColor...

  • Claret Montage Dual Filter gains support from study. FORD, OMAR // Medical Device Daily;5/21/2013, Vol. 17 Issue 98, p1 

    The article reports on a study by cardiologist Nicolas Van Mieghem which can provide credence to a device for cleaning up embolic debris after Transcatheter Aortic Valve Replacement (TAVR) developed by Santa Rosa, California-based medical device company Claret Medical. Van Mieghem's study...

  • PRODUCT BRIEFS.  // Medical Device Daily;12/19/2013, Vol. 17 Issue 244, p8 

    The article presents information on products in the medical device industry, including a U.S. Food and Drug Administration clearance obtained by Oticon Medical to market its Ponto Plus bone anchored sound processors, results of two clinical trials on the iFuse Implant System from medical device...

  • NeuroSigma has positive results for its eTNS trial. FORD, OMAR // Medical Device Daily;2/ 4/2013, Vol. 17 Issue 23, p1 

    The article reports on the positive results of the NeuroSigma Inc.'s external Trigeminal Nerve Stimulation (eTNS) clinical study for drug-resistant epilepsy (DRE) treatment. It states that the DRE is a serious medical disorder that has affected 30% of the estimated 50 million people with...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics